Obesity market growth prompts Novo Nordisk to lift guidance again

10 August 2023
novo_nordisk_copenhagen_large

Danish drugmaker Novo Nordisk (NOV: N) has reported sales in line with expectations at 108 billion Danish kroner ($15.98 billion) for the first six months in 2023, up 30% from the same period a year earlier.

Earnings per share were 17.41 Danish kroner, up 44% but slightly below expectations.

Sales of semaglutide, the company’s glucagon-like peptide-1 receptor agonist, are a major reason for Novo Nordisk’s stellar performance, both under its Wegovy guise as a breakthrough obesity drug and as Ozempic to treat type 2 diabetes and prevent major cardiovascular problems.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical